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Introduction
 
Changes in hormonal status, insulin resistance, physical activity
and food intake result in an approximately two- to three-fold
increase in insulin requirement during pregnancy, starting
from weeks 16–18 of gestation. These physiological changes
lead to gestational diabetes mellitus (GDM) when the insulin
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Aims
 
We hypothesized that an increased serum insulin level in early pregancy
reflects an increased demand on the compensatory capacity of the pregnant
woman, and can serve as a predictor of gestational diabetes mellitus (GDM).
 
Methods
 
A 2-h, 75-g oral glucose tolerance test (OGTT), with fasting and 2-h
postprandial serum insulin determination, was performed in 71 pregnant women
with one or more risk factors for GDM before gestation week 16. In 64 patients,
subsequent OGTTs were performed at gestation weeks 24–28, and in the event
of a negative result, at gestation weeks 32–34.
 
Results
 
Insulin determination at fasting and at 120 min had sensitivities of
69.2% and 92.3%, and specificities of 96.4% and 85.7%, respectively, for the
prediction of GDM at gestation weeks 24–28. The sensitivities decreased to
33.3% and 75.0%, respectively, for the prediction of GDM at gestation weeks
32–34. Insulin determination at fasting and at 120 min had positive predictive
values of 0.90 and 0.75, respectively, for the prediction of GDM at gestation
weeks 32–34. The negative predictive values of fasting and 120-min serum
insulin determination at gestation week 
 
≤
 
 16 were 0.87 and 0.96, respectively, for
the prediction of GDM at gestation weeks 24–28. Increased serum insulin levels
both at fasting and 120 min before gestation week 16 were very strong predictive
factors for GDM by gestation weeks 32–34 with an odds ratio of 16.6 and 13.3,
respectively.
 
Conclusions
 
Serum insulin determination at gestation week 
 
≤
 
 16 is an easy and
reliable method with which to predict GDM in a high-risk group. Despite a neg-
ative OGTT, patients with an elevated fasting and/or 120-min serum insulin
level at gestation week 
 
≤
 
 16 should be managed in the same way as those with
GDM. Considering the very high negative predictive value of the method,
patients with a normal fasting and/or 120-min serum insulin level at gestation
week 
 
≤
 
 16 should undergo an OGTT only at gestation weeks 32–34.
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requirement exceeds its secretion. Although GDM can develop at
any time during pregnancy, depending on the compensatory capac-
ity of the pregnant woman, it most often develops in the third tri-
mester, as the insulin requirement is the highest at that time [1].
It is recommended that those patients with risk factors for
GDM, such as a family history of diabetes, a history of an
adverse perinatal outcome (macrosomia, malformation,
polyhydramnios, stillbirth or missed abortion), a maternal age
> 35 years, obesity, hypertension or glycosuria, undergo
screening at the first prenatal visit [2–4]. Subsequent testing is
recommended at gestation weeks 24–28 if the screening in
early pregnancy yields a normal result. However, a negative
oral glucose tolerance test (OGTT) with an increased fasting
and/or postprandial serum insulin level reflects an increased
demand on the compensatory capacity of the pregnant
woman. We hypothesized that an increased serum insulin level
at screening in early pregancy can predict GDM.
The aim of this study was to determine the predictive value
of the serum insulin level before gestation week 16 in a high-
risk group in the identification of subsequent GDM.
 
Methods
 
This prospective observational study was carried out between
1 January 2001 and 28 February 2002. The study protocol was
approved by our local ethics committee. All pregnant women
referred to our special Diabetic Pregnancy Outpatient Depart-
ment who displayed one or more risk factors for GDM (
 
n
 
 = 90)
were enrolled in the study after informed consent. Nineteen of
the 90 patients were excluded from the study as they were
referred to our department after gestation week 16 or had had
GDM in a previous pregnancy. The pregnant women who had
had GDM in a previous pregnancy were managed as patients
with pregestational diabetes mellitus. After their informed con-
sent had been given, a 2-h, 75-g OGTT was performed in 71
pregnant women before gestation week 16 according to the
World Health Organization (WHO) criteria with serum insulin
determination at fasting and at 2 h [5,6]. The pregnant women
were instructed to consume at least 150 g carbohydrate/day for
3 days and to fast overnight for 10–12 h on the day before the
OGTT. Plasma glucose and insulin levels were obtained by
repeated venepuncture at fasting and 120 min after ingestion of
a 75-g glucose solution over 5 min. Glucose levels were deter-
mined by the GOD-POD (glucose oxidase–peroxidase) colori-
metric method (RANDOX Laboratories Ltd, Crumlin, UK) on
venous blood collected into sodium fluoride. Both the inter-
assay and the intra-assay coefficients of variation (CV) were
< 2%. Patients were considered to have GDM in the event of a
glucose level of 
 
≥
 
 7.0 mmol/ l at fasting and/or of 
 
≥
 
 7.8 mmol/ l
at 120 min, according to the WHO criteria. Seven patients were
excluded from further analysis as GDM was diagnosed in this
first OGTT before gestation week 16. Serum insulin levels were
determined by chemiluminescent immunoassay (DPC Immulite
1000; Diagnostic Products Co., Los Angeles, CA, USA), with
an interassay CV of 7.6% and an intra-assay CV of 4.8%. This
method has a cross-reaction with proinsulin of 8.5% and has
no cross-reaction with C-peptide and glucagon as stated in the
original description of the method. Serum insulin levels of
 
≥
 
 30 mU/l at fasting and 
 
≥
 
 70 mU/l at 120 min were considered
to be hyperinsulinaemic based on our laboratory reference
ranges for a population of body mass index (BMI) 
 
≥
 
 27 kg/m
 
2
 
,
which are similar to the values given in the protocol description
of Immulite and to that described by Ascaso 
 
et al
 
. in an obese
non-pregnant population [7] with normal glucose metabolism.
Subsequent OGTTs without insulin determination were per-
formed in the remaining 64 pregnant women at gestation weeks
24–28, and for those with a normal result then (
 
n
 
 = 48) at
gestation weeks 32–34. Glycated haemoglobin (HbA
 
1c
 
) levels
were also determined on the fasting blood samples. HbA
 
1c
 
 was
assayed by microparticle enzyme immunoassay (Abbott Labo-
ratories, Abbott Park, IL, USA), with an interassay CV of 6.4%
and an intra-assay CV of 4.4% and reference range < 6.0%.
The incidences of the following risk factors for GDM were
analysed: any family history of Type 2 diabetes, a history of a large
neonate (
 
≥
 
 4000 g), a history of an adverse perinatal outcome
(missed abortion, malformation, polyhydramnios, stillbirth
or preterm delivery), obesity {prepregnant BMI [weight (kg)/
height
 
2
 
 (m
 
2
 
)] 
 
≥
 
 30}, age 
 
≥
 
 35 years and glycosuria.
The maternal BMI was calculated and analysed by means of
the WHO/NIH classification of overweight and obesity [8–10].
The prepregnant weight or that recorded at the first antenatal
visit was used for calculation of the maternal BMI.
Statistical analysis was by 
 
ANOVA
 
 and multiple logistic regression
methods using the Stata Software Package (StataCorp LP, College
Station, TX, USA). Hosmer–Lemeshow goodness-of-fit test was
performed to check models. The sensitivity, specificity, and
positive and negative predictive values of the fasting and post-
load insulin level in predicting GDM at gestation weeks 24–28
and 32–34 were calculated. All data are presented as the mean
 
±
 
 
 
SD
 
. Statistical significance was set at the 95% level (
 
P <
 
 0.05).
 
Results
 
GDM was diagnosed in 43 (60.5%) of the 71 pregnant women
with one or more risk factors for GDM who were referred to
our department at gestation week 
 
≤
 
 16: in seven (16.3%) at the
first OGTT before gestation week 16, in 13 (30.2%) at gesta-
tion weeks 24–28, and in 23 (53.5%) at gestation weeks 32–34.
Seven women had GDM by week 16, 20 by weeks 24–28 and
43 by gestation weeks 32–34. The pregnant women were
divided into subgroups on the basis of the gestational age at the
onset of GDM (Table 1). The HbA
 
1c
 
, plasma glucose and
insulin levels both at fasting and at 120 min decreased with
increase in gestational age at the diagnosis of GDM.
The incidence of subsequent GDM was analysed in preg-
nant women with a negative result (
 
n
 
 = 64) on the first OGTT
at gestation week 
 
≤
 
 16. The pregnant women were divided into
three subgroups on the basis of the fasting and 120-min serum
insulin levels at gestation week 
 
≤
 
 16: normal at both fasting
and 120 min, normal at fasting but increased at 120 min, and
both increased (Table 2). No woman had increased fasting but
normal 120-min serum insulin levels. In the subgroup of 13
women with increased serum insulin levels both at fasting and
at 120 min, GDM occurred in nine at gestation weeks 24–28,
and only one did not develop GDM during the pregnancy. In
the 18 women with normal fasting and increased 120-min
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Table 1 Demographic, morphometric and metabolic parameters at gestation week < 16 of pregnant women grouped on the basis of the time of onset 
of gestational diabetes mellitus (GDM)
Onset of GDM
Non-GDMAt gw ≤ 16 At gw 24–28 At gw 32–34
No. of cases 7 13 23 28
Age (years) 27.3 ± 5.1 29.8 ± 5.3 29.0 ± 6.0 28.9 ± 5.8
Body mass index (kg/m2) 27.1 ± 6.6 32.0 ± 7.5* 29.5 ± 6.4 28.2 ± 5.3
Gestational age at first investigation (weeks) 12.0 ± 3.3 13.0 ± 2.0 13.4 ± 2.0 13.1 ± 2.3
HbA1c (%) 7.7 ± 2.2***†‡‡ 6.2 ± 0.9 6.0 ± 0.5 5.7 ± 0.5
Plasma glucose (mmol/ l )
Fasting 5.8 ± 1.7***† 5.4 ± 0.7*** 4.9 ± 0.5 4.6 ± 0.4
120 min 8.8 ± 1.2***†††‡‡ 7.1 ± 0.4*** 6.2 ± 1.2 5.6 ± 1.0
Serum insulin (mU/l)
Fasting 31.8 ± 9.0***†† 32.2 ± 6.6***††† 21.5 ± 8.0 16.1 ± 6.3
120 min 96.5 ± 11.6***† 94.7 ± 22.7***†† 69.0 ± 24.0** 47.4 ± 22.4
Treatment of GDM
Diet only 3 9 23
Diet and insulin 4 4 0
No. of cases with risk factor
1 risk factor 4 7 14 19
≥ 2 risk factors 3 6 9 9
gw, gestational weeks.
Significance levels were calculated using Bonferoni method.
Difference from the non-GDM group: *P < 0.05; **P < 0.01; ***P < 0.001.
Difference from the group with GDM at gw 32–34: †P < 0.05; ††P < 0.01; †††P < 0.001.
Difference from the group with GDM at gw 24–28: ‡P < 0.05; ‡‡P < 0.01; ‡‡‡P < 0.001.
Serum insulin level (mU/l) at gw ≤ 16
≥ 30 fasting 
≥ 70 120 min
< 30 fasting 
≥ 70 120 min
< 30 fasting 
< 70 120 min
No. of cases 13 18 33
GDM at gw 24–28 9 3 1
GDM at gw 32–34 3 12 8
Non-GDM cases 1 3 24
Age (years) 30.0 ± 5.2 29.2 ± 5.6 28.8 ± 6.1
Body mass index (kg/m2) 32.4 ± 7.3* 30.2 ± 6.5 27.9 ± 5.3
Glucose (mmol/l)
Fasting 5.2 ± 0.8* 5.0 ± 0.6 4.7 ± 0.4
120 min 6.8 ± 0.8** 6.6 ± 1.0** 5.6 ± 1.1
HbA1c (%) 6.1 ± 1.0 6.0 ± 0.4 5.9 ± 0.6
No. of cases with risk factor
1 risk factor 6 (46.2%) 10 (55.6%) 24 (72.7%)
≥ 2 risk factors 7 (53.8%) 8 (44.4%) 9 (27.3%)
gw, gestational weeks; GDM, gestational diabetes mellitus.
Significance levels were calculated using Bonferoni method.
Difference from the group with serum insulin level < 30 mU/l and < 70 mU/l at fasting and at 
120 min, respectively, at gw ≤ 16: *P < 0.05; **P < 0.01; ***P < 0.001.
Table 2 Age, body mass index, HbA1c, and 
glucose levels of pregnant women divided into 
subgroups on the basis of serum insulin level at 
gestational weeks ≤ 16
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serum insulin levels, GDM was present at gestation weeks 24–
28 in only three but was present in 12 women at gestation
weeks 32–34. Of the 33 cases with normal fasting and 120-
min serum insulin levels, 24 did not develop GDM. GDM was
apparent in one of these 33 cases at gestation weeks 24–28,
and in eight cases at gestation weeks 32–34.
The sensitivity, specificity, and positive and negative predic-
tive values of increased fasting or 120-min serum insulin levels
for the prediction of glucose intolerance by gestation weeks
24–28 and 32–34 are shown in Table 3. Increased fasting
serum insulin level had the higher positive predictive value com-
pared with increased 120-min insulin level for both gestation
weeks 24–28 and 32–34. Higher negative predictive values for
both gestation weeks 24–28 and 32–34 were found when the
serum insulin level at 120 min was increased rather than the
fasting value.
The sensitivity, specificity, and positive and negative predic-
tive values of increased fasting serum insulin levels for the pre-
diction of impaired fasting glucose (IFG) by gestation weeks
24–28 and 32–34 were also calculated. Increased fasting serum
insulin (> 30 mU/l) predicted IFG at gestation weeks 24–28
with a sensitivity of 94%, specificity of 50%, positive predictive
value 0.37 and negative predictive value 0.96. Increased fast-
ing serum insulin (> 30 mU/l) predicted IFG at gestation weeks
32–34 with a sensitivity of 76%, specificity of 87%, positive
predictive value 0.65 and negative predictive value 0.92.
The prevalence of risk factors for GDM were as follows:
family history of diabetes 49.3% (35 out of 71); obesity (prepreg-
nant BMI 
 
≥
 
 30 kg/m
 
2
 
) 46.5% (33 out of 71); age 
 
≥
 
 35 years
21.1% (15 out of 71); glycosuria 15.5% (11 out of 71); history
of large neonate (
 
≥
 
 4000 g) 9.9% (seven out of 71); history of
adverse perinatal outcome (included missed abortion, malfor-
mation, stillbirth) 5.6% (four out of 71). Twenty-seven of the
71 women had more than one risk factor for GDM.
Univariate analysis showed that fasting and 120-min
plasma glucose, HbA
 
1c
 
, BMI, fasting insulin with a range of
odds ratios (OR) of 1.4–31.0 and wide confidence intervals
(CI) significantly predicted GDM at 24–28 and 32–34 weeks,
except for BMI for GDM at gestation weeks 32–34. Plasma
glucose levels and serum insulin levels at fasting and at
120 min, HbA
 
1c
 
 and BMI were used in the multiple logistic
regression analysis. Increased serum insulin level at fasting
(OR 16.6, 95% CI 2.06, 134.2) was the best predictor of
GDM at gestation weeks 24–28 in the multiple logistic regres-
sion model. In addition, increased serum insulin level at
120 min (OR 13.3, 95% CI 3.07, 57.9) was the best predictor
of GDM by gestation weeks 32–34. There was no relationship
between raised HbA
 
1c
 
 and GDM at either gestation weeks 24–
28 (OR 4.3, 95% CI 0.67, 27.8) or weeks 32–34 (OR 1.6,
95% CI 0.44, 5.53). BMI, plasma glucose level at fasting and
120 min did not enter the multiple regression model. All
models had a good fit.
 
Discussion
 
GDM has been characterized as the onset or recognition of
glucose intolerance during the current pregnancy [11]. GDM
is a heterogeneous entity which includes both pregnancy-
induced glucose intolerance and undiagnosed alteration of the
carbohydrate metabolism discovered during pregnancy. The
increase in the insulin level starts at gestation weeks 16–18
[12]. Hyperinsulinaemia after this gestational age reflects an
approximately two- to three-fold increase in the insulin level,
induced by pregnancy. Hyperinsulinaemia before this gesta-
tional age demonstrates that the patient is really hyperinsu-
linaemic, independent of the pregnancy.
Hyperinsulinaemia is a significant risk factor for diabetes
mellitus. We consider hyperinsulinaemia in the non-pregnant
state or before gestation weeks 16–18 to be a risk factor for
GDM, as it implies insulin resistance. We hypothesized that
hyperinsulinaemia in a pregnant woman merely requires time
to transform to GDM.
Until now only a few studies have used the insulin level to
predict insulin resistance or GDM. Several authors have exam-
ined the insulin level during and after pregnancy in patients
with GDM in order to predict the development of diabetes
mellitus [13,14]. However, we have found no prospective evalu-
ation of the fasting insulin level or the insulin response to a 75-
g OGTT in early pregnancy to predict later GDM during the
index pregnancy.
Increased serum insulin level at gw ≤ 16
At fasting (≥ 30 mU/l) At 120 min (≥ 70 mU/l)
GDM by the gestational weeks
24–28 32–34 24–28 32–34
Sensitivity, % 69.2 33.3 92.3 75.0
Specificity, % 96.4 96.4 85.7 85.7
Positive predictive value 0.9 0.92 0.75 0.87
Negative predictive value 0.87 0.53 0.96 0.73
gw, gestational weeks; GDM, gestational diabetes mellitus.
Table 3 Sensitivity, specificity, and positive 
and negative predictive values of serum insulin 
levels fasting and at 120 min before gestational 
weeks 16 for prediction of a glucose intolerance by 
gestational weeks 24–28 and 32–34
© 2005 Diabetes UK. Diabetic Medicine, 22, 1434–1439
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Ergin et al. examined the insulin response to a 100-g 3-h
OGTT in 120 Turkish women between 24 and 28 weeks’
gestation [15]. The fasting insulin level and insulin resistance
were similar in patients with a single abnormal value during
the OGTT and those with GDM.
Kirwan et al. investigated insulin sensitivity indicated by an
OGTT and also fasting glucose/insulin levels in an effort to
predict insulin sensitivity in women before and during preg-
nancy [16]. They repeated a 2-h euglycaemic-hyperinsulinaemic
clamp and a 120-min OGTT (a 75-g load in prepregnancy,
and a 100-g load in pregnancy) in 15 women in prepregnancy
and in both early (12–14 weeks) and late (34–36 weeks) preg-
nancy. They found that the insulin sensitivity indicated by the
OGTT is a better indicator of insulin sensitivity than the fast-
ing glucose and insulin values. However, the use of such an
inconvenient method clearly limits the numbers that can be
studied.
Clark et al. found that patients with GDM had higher insu-
lin and C-peptide levels both at fasting and at 2 h compared
with non-GDM patients [17]. They determined insulin and C-
peptide between 16 and 33 weeks’ gestation, and found that
these variables were predictive of GDM individually. They
suggested that GDM should be looked upon as a component
of the syndrome of insulin resistance.
Swinn et al. concluded that the excessive secretion of insulin
precursors characterizes and predicts GDM [18]. They exam-
ined the insulin, the intact proinsulin and the 32,33-split
proinsulin response to an OGTT in 64 women with GDM and
in 154 non-GDM control subjects of comparable age and
BMI. The women with GDM were characterized by higher
plasma insulin and intact proinsulin levels at 120 min and by
elevated 32,33-split proinsulin levels both at fasting and at
120 min. These insulin secretion abnormalities in GDM
patients are similar to those seen in non-pregnant subjects with
impaired glucose tolerance. They also measured insulin and
proinsulin-like molecules in women with a 1-h glucose level of
> 7.7 mmol/ l after a 50-g glucose challenge at 28–32 weeks
of gestation. The percentage of total insulin-like molecules
accounted for by proinsulin-like molecules was significantly
elevated in those women in whom a subsequent OGTT
showed GDM compared with those in whom the later OGTT
was normal. To improve the predictive power of screening
tests for GDM, Swinn et al. suggested the incorporation of a
measurement of the percentage of proinsulin-like molecules in
the routine 50-g screening test. In our view, the incorporation
of serum insulin determinations at fasting and at 120 min in
the screening protocol for GDM seems worthwhile and more
applicable than the calculation of proportions of proinsulin, or
the use of expensive and inconvenient methods. However, this
is applicable only in pregnant women with a risk factor for
GDM before 16 weeks’ gestation.
We found a positive correlation between serum insulin level
and the subsequent manifestation of GDM. The higher the
serum insulin level, the earlier the manifestation of GDM.
Most (83.3%) of the pregnant women with an elevated serum
insulin level at 120 min subsequently developed GDM by
gestation weeks 32–34. GDM was present at gestation weeks
24–28 in 69.2% of those with elevated serum insulin levels
both at fasting and at 120 min, and at gestation weeks 32–34
in 66.7% of those with a normal fasting level but an increased
120-min serum insulin level at ≤ 16 gestation week. However,
GDM did not develop at all in 72.7% of those with normal
serum insulin levels both at fasting and at 120 min at ≤ 16
gestation week.
Increased serum insulin levels both at fasting and 120 min
before gestation week 16 were strongly predictive of the develop-
ment of GDM by gestation weeks 32–34 with an OR of 16.6
and 13.3, respectively.
As a fasting plasma glucose level of 5.6 mmol/ l is the gener-
ally accepted cut-off value for IFG, we analysed fasting serum
insulin levels in order to predict the subsequent development
of IFG [19]. We found that increased fasting serum insulin
level (> 30 mU/l) at gestation week ≤ 16 has very good sensi-
tivity (94%) and poor specificity (50%) to predict IFG at ges-
tation weeks 24–28. The sensitivity decreased to 76% but the
specificity increased to 87% for the development of IFG at ges-
tation weeks 32–34. Negative predictive values were very high
at both gestation weeks 24–28 and 32–34. However, IFG is
not a diagnostic criterion for GDM, so pregnant women with
IFG should undergo a subsequent OGTT.
Measurement of fasting and 2-h insulin during an OGTT
before gestation week 16 might reduce the number of sub-
sequent screening tests for GDM, in addition to facilitating
optimal timing of the subsequent screening procedures.
Furthermore, earlier introduction of the appropriate manage-
ment of the pregnant women may prevent some complications
of GDM, such as increased fetal growth.
Conclusions
Fasting and 2-h serum insulin measurements at ≤ 16 gestation
week is an easy and reliable method with which to predict
GDM in patients with a risk factor for GDM. Because of the
very high positive predictive value of the method for GDM at
gestation weeks 32–34, pregnant women with an elevated fast-
ing and/or 120-min serum insulin level at ≤ 16 gestation week
should be managed in the same way as those with a diagnosis
of glucose intolerance, in spite of normal blood glucose values
during the OGTT. Given the very high negative predictive
value of the method at gestation weeks 24–28, pregnant
women with normal serum insulin levels at fasting and at
120 min at ≤ 16 gestation week should undergo a subsequent
OGTT only at gestation weeks 32–34. Because obesity is one
the most frequent risk factors for GDM, a calorie-restricted
diet might be considered for a pregnant women with obesity,
independently of the results of the OGTT.
Competing interests
None declared.
Clinical practice 1439
© 2005 Diabetes UK. Diabetic Medicine, 22, 1434–1439
Acknowledgements
We thank Ádám Tabák Gy. for statistical advice and Professor
Gyula Tamás for scrutinizing the manuscript.
References
1 Gabbe SG. Management of diabetes mellitus in pregnancy. Am J
Obstet Gynecol 1985; 153: 824–828.
2 Ostlund I, Hanson U. Occurrence of gestational diabetes mellitus and
the value of different screening indicators for the oral glucose
tolerance test. Acta Obstet Gynecol Scand 2003; 82: 103–108.
3 American College of Obstetricians and Gynecologists. Diabetes and
pregnancy. ACOG Technical Bulletin. Int J Gynecol Obstet 1995;
48: 331–339.
4 Bartha JL, Martinez-del-Fresno P, Comino-Delgado R. Postpartum
metabolism and autoantibody markers in women with gestational
diabetes mellitus diagnosed in early pregnancy. Am J Obstet Gynecol
2001; 184: 965–970.
5 Nahum GG, Huffaker BJ. Correlation between first- and early
third-trimester glucose screening test results. Obstet Gynecol 1990;
76: 709–713.
6 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of
diabetes mellitus and its complications. I. Diagnosis and classifica-
tion of diabetes mellitus provisional report of a WHO consultation.
Diabet Med 1998; 15: 539–553.
7 Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Dia-
gnosing insulin resistance by simple quantitative methods in subjects
with normal glucose metabolism. Diabetes Care 2003; 26: 3320–3325.
8 Report of a WHO Consultation: Definition, Diagnosis and Classifi-
cation of Diabetes Mellitus and its Complications. Part 1: Diagnosis
and Classification of Diabetes Mellitus. Geneva: World Health
Organization, Department of Noncommunicable Disease Surveil-
lance, 1999.
9 World Health Organization. Obesity. Preventing and Managing the
Global Epidemic. Report of a WHO consultation on obesity. Geneva:
WHO, 1998.
10 U.S. National Institutes of Health. Clinical Guidlines for the Identi-
fication, Evaluation, and Treatment of Overweight and Obesity in
Adults. Bethesda, MD: National Institutes of Health, 1998.
11 Metzger BE. Summary and recommendations of the Third Inter-
national Workshop-Conference on Gestational Diabetes Mellitus.
Diabetes 1991; 40: 197–201.
12 Baird JD. Some effects of metabolism and hormonal adaptaion preg-
nancy. Acta Endocrinol 1986; 277: 11–18.
13 Buchanan TA, Xiang A, Kjos SL, Lee WP, Trigo E, Nader I et al. Ges-
tational diabetes: antepartum characteristics that predict postpartum
glucose intolerance and type 2 diabetes in Latino women. Diabetes
1998; 47: 1302–1310.
14 Damm P, Kuhl C, Hornnes P, Molsted-Pedersen L. A longitudinal
study of plasma insulin and glucagon in women with previous gesta-
tional diabetes. Diabetes Care 1995; 18: 654–665.
15 Ergin T, Lembet A, Duran H, Kuscu E, Bagis T, Saygili E, Batioglu S.
Does insulin secretion in patients with one abnormal glucose
tolerance test value mimic gestational diabetes mellitus? Am J Obstet
Gynecol 2002; 186: 204–209.
16 Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM. Clinically
useful estimates of insulin sensitivity during pregnancy: validation
studies in women with normal glucose tolerance and gestational dia-
betes mellitus. Diabetes Care 2002; 24: 1602–1607.
17 Clark CM Jr, Qiu C, Amerman B, Porter B, Fineberg N, Aldasouqi S,
Golichowski A. Gestational diabetes: should it be added to the
syndrome of insulin resistance? Diabetes Care 1997; 20: 867–
871.
18 Swinn RA, O’Rahilly S. Excessive secretion of insulin precursors
characterizes and predicts gestational diabetes. Diabetes 1995; 44:
911–915.
19 American Diabetes Association. Diagnosis and classification of
diabetes mellitus. Diabetes Care 2004; 27: S5–S10.
